[Oral ciprofloxacin therapy in salpingitis].
Thirty patients with clinical pelvic inflammatory disease were studied. Diagnosis was confirmed by laparoscopy. To determine the microbiological etiology, swab specimen for detection of aerobic, anaerobic and chlamydial infections were obtained from the endocervix, fimbriae and cul-de-sac. In 22 of 30 patients, microorganisms were detected. The patients received ciprofloxacin 2 X 750 mg p.o. daily at 12 hours interval for 10 days. During and after therapy, bacteriological examinations of the endocervix were performed. Based on the microbiological evaluation and clinical aspects, the bacteriological response and clinical efficacy were 86%. Laboratory analysis showed no alterations of blood values. As side effects we noticed gastrointestinal complaints (6/30), candidiasis vulvovaginalis (6/30), allergic exanthema (5/30) and non-bacterial cystitis (2/30). Oral ciprofloxacin-monotherapy proved to be safe and effective in pelvic inflammatory disease.
De Wilde
R
R
Geburtshilflich-Gynäkologischen Abteilung des Krankenhauses Bethesda Wuppertal-Elberfeld, Westfälischen Wilhelms-Universität Münster.
D000284:Administration, Oral; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy; D002939:Ciprofloxacin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D012488:Salpingitis / Q000188:drug therapy*
D002939:Ciprofloxacin
Orale Ciprofloxacin-Therapie bei Salpingitis.